Immune Globulin Subcutaneous (Human), 20%
170903
Phase 3 mab completed
Quick answer
Immune Globulin Subcutaneous (Human), 20% for Primary Immunodeficiency Diseases (PID) is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Primary Immunodeficiency Diseases (PID)
- Phase
- Phase 3
- Modality
- mab
- Status
- completed